Brief: Hua Medicine Says Dorzagliatin's Phase III Metformin Combination Trial Met Primary Efficacy And Safety End Point
01/07/2020 11:28
July 1 (Reuters) - Hua Medicine 2552.HK :
* HUA MEDICINE- DORZAGLIATIN'S PHASE III METFORMIN
COMBINATION
TRIAL MET PRIMARY EFFICACY AND SAFETY END POINT
Source text for Eikon: ID:nHKS71cvk1
Further company coverage: 2552.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hua Medicine
See all newsBrief: Hua Medicine Expects Loss Of RMB30.2 Mln For HY
Brief: Hua Medicine Posts Profit For The Year RMB1.11 Billion
Brief: Hua Medicine Says Dorzagliatin Approved For Marketing In Hong Kong SAR
Brief: Hua Medicine Posts H1 Revenue Of RMB 217.4 Million
Brief: Hua Medicine Expects RMB1,184.1 Million Profit For HY